

OCT 2 9 2002

TECH CENTER 1600/2900

Docket No.: 208254US0

OBLON SPIVAK **McClelland** MAIER NEUSTADT P.C.

ATTORNEYS AT LAW

ASSISTANT COMMISSIONER FOR PATENTS WASHINGTON, D.C. 20231

RE: Application Serial No.: 09/850,031

Applicants: Nobuhisa SHIMBA, et al.

Filing Date: May 8, 2001

For: METHOD FOR ISOTOPE LABELING OF PROTEIN

WITH ENZYME Group Art Unit: 1651 Examiner: WEBER

SIR:

Attached hereto for filing are the following papers:

Response to Restriction Requirement (2 pp.)

Our check in the amount of \$0.00 is attached covering any required fees. In the event any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 C.F.R 1.136 for any necessary Extension of Time to make the filing of the attached documents timely, please charge or credit the difference to our Deposit Account No. 15-0030. Further, if these papers are not considered timely filed, then a petition is hereby made under 37 C.F.R. 1.136 for the necessary extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

Norman F. Oblon

Registration No. 24,618

Vincent K. Shier, Ph.D. Registration No. 50,552

22850

(703) 413-3000 (phone) (703) 413-2220 (fax)

OUT 2 9 2002

DOCKET NO.: 208254US0



TECH CENTER 1600/2900

TENT & TRADEMARK OFFICE IN THE UNITED

IN RE APPLICATION OF:

Nobuhisa SHIMBA, et al.

: GROUP ART UNIT: 1651

SERIAL NO.: 09/850,031

FILED: MAY 8, 2001

: EXAMINER: WEBER

FOR: METHOD FOR ISOTOPE LABELING OF PROTEIN WITH ENZYME

RESPONSE TO RESTRICTION REQUIREMENT

ASSISTANT COMMISSIONER FOR PATENTS WASHINGTON, D.C. 20231

SIR:

Responsive to the Official Action dated September 26, 2002, Applicants elect, with traverse, Group I, Claims 1-11, for further prosecution.

REMARKS

The Office has required restriction in the present application as follows:

Group I:

Claims 1-11, drawn to a method for isotopically labeling a protein; and

Group II:

Claims 12-15, drawn to a method of determining the substrate

specificity of transglutaminase.

Applicants elect, with traverse, Group I, Claims 1-11, for further prosecution.

The Office has characterized the inventions of Groups I-II as unrelated. However, the Office has not provided sufficient reasons and/or examples to support this assertion. The Office has merely stated the conclusion. Accordingly, the Office has failed to meet the burden necessary in order to sustain the Restriction Requirement. Applicants respectfully submit that the Restriction Requirement should be withdrawn.